AMO a Hold Post-Abbott Deal

Tags: eye, abt
14 Jan 11:23pm
Posted by ZacksResearch
0 Comments
Read original blog entry

Advanced Medical Optics, Inc., or AMO (EYE) entered into a definitive agreement to be acquired by Abbott Laboratories (ABT). Price appreciation on the stock is limited to the all cash transaction price of $22 per share or approximately $2.8 billion.

Our target price is equal to this cash transaction price and assumes the transaction will close. The company is a global leader in the development, manufacture, and marketing of medical devices for the eye and contact lens care products.

The stock is already trading near its cash transaction price. Thus, our target price is equal to this cash transaction price of $22 per share.

Read the full analyst report on EYE

Read the full analyst report on ABT




Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries